<DOC>
	<DOCNO>NCT02911428</DOCNO>
	<brief_summary>The purpose study evaluate post-vaccination immune status different time point subject immunized Ebola Virus Disease ; select optimal regimen product administration ; , ass safety medicinal product GamEvacVector-Based Vaccine Ebola Virus Disease , 0.5 ml+0.5 ml/dose , follow immunization half ( 0.25 ml+0.25 ml/dose ) full ( 0.5 ml+0.5 ml/dose ) therapeutic dos .</brief_summary>
	<brief_title>Open Study Duration Immunity After Vaccination With GamEvac</brief_title>
	<detailed_description>This clinical trial design open study evaluate duration immunity persistence follow administration medicinal product GamEvac Vector-Based Vaccine Ebola Virus Disease . It observational study ; intervention plan course common clinical practice study period ; investigate therapeutic agent special method examination use study , except blood sample procedure specify Protocol . Only patient sign information consent form participation study inform physician objective method project involve study . The study consist single stage design follow-up period observe volunteer vaccinate course evaluation safety , reactogenic property immunogenicity product GamEvac Vector-Based Vaccine Ebola Virus Disease dosages 0.25 ml 0.5 ml , study Protocol 02-E-2015 October-November 2015 . Vaccination make within present study . Screening volunteer require : study involve many volunteer possible ( 60 subject ) immunize earlier GamEvac Vector-Based Vaccine Ebola Virus Disease , provide medical contraindication blood sampling . Study Schedule Visit 1 ( outpatient ) : goal visit ass whether patient meet inclusion/exclusion criterion . All procedure carry upon receipt inform consent form sign patient . The visit hold 12 month vaccination . Visit 2 ( outpatient ) : 18 month vaccination . Visit 3 ( outpatient ) : 24 month vaccination . The duration immunity persistence follow product administration assess healthy volunteer base measurement specific antibody titer . ELISA method 12 , 18 24 month vaccination vs. baseline value ; virus neutralization reaction 12 month vaccination vs. baseline value .</detailed_description>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female age 1856 earlier vaccinate medicinal product GamEvac dosages 0.25 ml 0.5 ml , study Protocol 02E2015 OctoberNovember 2015 . Written inform consent sign patient prior involvement study Absence early vaccination medicinal product GamEvac dosages 0.25 ml 0.5 ml , study Protocol 02E2015 OctoberNovember 2015 . Presence concomitant illness could preclude obtain venous blood sample affect study process : ( critical patient 's condition , seizure , agitate state , blood loss shock different origin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ebola</keyword>
	<keyword>Ebola Virus Vaccines</keyword>
	<keyword>Haemorrhagic Fever</keyword>
	<keyword>Ebola Infection</keyword>
	<keyword>GP protein , Ebola virus</keyword>
</DOC>